Periodontal pathogens are likely to be responsible for the development of ankylosing spondylitis

scientific article published on 21 May 2015

Periodontal pathogens are likely to be responsible for the development of ankylosing spondylitis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2174/1573397111666150522094821
P932PMC publication ID4997922
P698PubMed publication ID26002454

P2093author name stringMesut Ogrendik
P2860cites workAtherosclerosis and infection: is the jury still not in?Q22241306
Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritisQ24672292
Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritisQ24813085
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathyQ34016674
Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritisQ34137749
HLA B27 in health and disease: a double-edged sword?Q34142454
Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patientsQ34289185
Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis.Q38081282
Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27.Q43468744
Association between ankylosing spondylitis and chronic periodontitis: a population-based studyQ43671171
Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound.Q44068950
Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessmentQ44342666
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative studyQ45334709
Periodontal disease in patients with ankylosing spondylitisQ46173445
Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints.Q54065722
THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARSQ61912643
A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effectQ68083745
Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsinQ69374297
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trialQ69924288
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled studyQ72231863
Adult periodontitis--specific bacterial infection or chronic inflammation?Q74342904
Treatment of ankylosing spondylitis with moxifloxacinQ80215253
P433issue1
P304page(s)47-49
P577publication date2015-05-21
P1433published inCurrent rheumatology reviewsQ27722414
P1476titlePeriodontal pathogens are likely to be responsible for the development of ankylosing spondylitis
P478volume11